Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Authors:
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (6) , 1749-1756
Abstract
Purpose: Clear cell renal cell carcinoma (ccRCC) is an immunogenic tumor that can progress in the presence of an intact host immune system. We previously reported that survivin and B7-H1 are independently associated with disease progression and death when expressed by ccRCC tumors. Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1. Experimental Design: Specimens from 298 patients who underwent nephrectomy for ccRCC between 1990 and 1994 were immunohistochemically stained for survivin and B7-H1. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of both markers with ccRCC death were assessed using Cox proportional hazards regression models. Results: At last follow-up, 94 patients died from ccRCC. Among the living patients, the median follow-up was 11.2 years (range, 0-15 years). There were 177 (59.4%) survivinLow/B7-H1−, 51 (17.1%) survivinHi/B7-H1−, 29 (9.7%) survivinLow/B7-H1+, and 41 (13.8%) survivinHi/B7-H1+ tumors. The 5-year cancer-specific survival rates for patients within each group were 89.3%, 59.7%, 70.0%, and 16.2%, respectively. Combined survivinHi/B7-H1+ expression was associated with ccRCC death univariately (risk ratio, 12.82; 95% confidence interval, 7.50-21.92; P < 0.001) and in multivariate analysis (risk ratio, 2.81; 95% confidence interval, 1.56-5.04; P < 0.001). SurvivinHi/B7-H1+ tumors exhibited increased levels of infiltrating mononuclear cells and survivin-specific T cells compared with survivinLow/B7-H1− tumors. Conclusion: Patients with survivinHi/B7-H1+ ccRCC tumors are at increased risk of ccRCC death. SurvivinHi/B7-H1+ tumors also harbor increased amounts of infiltrating mononuclear cells and survivin-specific T cells relative to survivinLow/B7-H1− tumors. Taken together, dual expression of survivin and B7-H1 can be used to predict ccRCC tumor aggressiveness.Keywords
This publication has 39 references indexed in Scilit:
- High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinomaCancer, 2006
- Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survivalCancer, 2006
- Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor AggressivenessClinical Cancer Research, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivinVaccine, 2005
- Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell ResponsesClinical Cancer Research, 2004
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMAJournal of Urology, 2001